Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. Phase I dose escalation study of ...

Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). This ...

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...

Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023. This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde ...

Oct. 14, 2010, 8:45 AM EDT / Source: GlobeNewswire CAMBRIDGE, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that results from its Phase 2 study of IPI ...

Lorlatinib appeared superior to crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer, according to an interim analysis of the randomized phase 3 CROWN study ...

Understanding a tumor’s genomics is becoming more critical in cancer care. Patients who have a certain mutation or rearrangement may benefit from some of the targeted therapies that the Food and Drug ...

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug ...

Groups Introduce $2 Million, Multi-Year Research Partnership and Open 2023 Request for Proposals NEW YORK, June 15, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and the ALK Positive ...

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.